Adherence at 6 months post index date | Adherence at 1 year post index date | |||
Unique studies (n) | OR (95% CI) | Unique studies (n) | OR (95% CI) | |
Apixaban vs dabigatran | 3 | 1.24 (1.07 – 1.45) | 5 | 1.76 (1.35 – 2.29) |
Rivaroxaban vs dabigatran | 5 | 1.39 (1.15 – 1.67) | 8 | 1.17 (0.38 – 3.60) |
Rivaroxaban vs apixaban | 4 | 0.80 (0.51 – 1.24) | 5 | 1.02 (0.79 – 1.33) |
Subanalysis: by adherence metric | ||||
MPR | ||||
Apixaban vs dabigatran | NA | NA | 2 | 2.49 (0.98 – 6.30) |
Rivaroxaban vs dabigatran | 1 | 1.63 (1.36 – 1.94) | 3 | 2.10 (1.56 – 2.81) |
Rivaroxaban vs apixaban | NA | NA | 2 | 0.90 (0.54 – 1.17) |
PDC | ||||
Apixaban vs dabigatran | 3 | 1.24 (1.07 – 1.45) | 3 | 1.41 (0.99 – 2.01) |
Rivaroxaban vs dabigatran | 4 | 1.34 (1.09 – 1.65) | 5 | 0.82 (0.18 – 3.69) |
Rivaroxaban vs apixaban | 4 | 0.80 (0.51 – 1.24) | 3 | 1.13 (0.71 – 1.82) |
MPR, medication possession ratio; PDC, proportions days covered.